Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
Journal
Liver cancer
Journal Volume
12
Journal Issue
1
Pages
44
Date Issued
2023-02
Author(s)
Ducreux, Michel
Zhu, Andrew X
Qin, Shukui
Ikeda, Masafumi
Kim, Tae-You
Galle, Peter R
Finn, Richard S
Chen, Ethan
Ma, Ning
Hu, Youyou
Li, Lindong
Abstract
In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. We used IMbrave150 data to investigate the safety and risk of viral reactivation or flare in infected patients treated with atezolizumab + bevacizumab or sorafenib.
Subjects
Atezolizumab; Bevacizumab; Post hoc analysis; Viral flare; Viral reactivation
SDGs
Publisher
KARGER
Type
journal article